SEC Form 4
Eikon Therapeutics, Inc. (EIKN) insider trading
In the 12 months to Oct 26, 2026, 6 EIKN insiders reported open-market purchases of $52.2M across 7 filings; no open-market sales were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $52.2M
- 7 filings
Who traded EIKN, and when
- Purchase
EIKN daily close from Feb 5, 2026 to Oct 26, 2026, between $5.92 and $16.26, last $5.92. 0 sale and 7 purchase filings by 6 insiders, marked at their filing dates. Tim Kutzkey, 10% owner: bought $25.9M across 1 filing, first filed Feb 9, 2026, last Feb 9, 2026. Peter Svennilson, 10% owner: bought $13.3M across 2 filings, first filed Feb 9, 2026, last Sep 8, 2026. Josh Wolfe, Director: bought $5.0M across 1 filing, first filed Feb 6, 2026, last Feb 6, 2026. Peter Hebert, 10% owner: bought $5.0M across 1 filing, first filed Feb 6, 2026, last Feb 6, 2026. Kenneth C. Frazier, Director: bought $2.0M across 1 filing, first filed Feb 6, 2026, last Feb 6, 2026. Foresite Capital Management V, LLC, 10% owner: bought $1.0M across 1 filing, first filed Feb 6, 2026, last Feb 6, 2026.
Largest mark · tap a row for others
Tim Kutzkey · 10% owner
Purchase $25,871,814
1,437,323 shares at $18.00 avg
Filed Feb 9, 2026 · traded Feb 6
Close on filing date $14.55
Tim Kutzkey · 10% owner
10% owner
$25.9M boughtPeter Svennilson · 10% owner
10% owner
$13.3M boughtJosh Wolfe · Director
Director
$5.0M boughtPeter Hebert · 10% owner
10% owner
$5.0M boughtKenneth C. Frazier · Director
Director
$2.0M boughtForesite Capital Management V, LLC · 10% owner
10% owner
$1.0M boughtOpen-market trades
7 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Tim Kutzkey | 10% owner | — | $25.9M | 1 | — | |
| Peter Svennilson | 10% owner | — | $13.3M | 2 | — | |
| Josh Wolfe | Director | — | $5.0M | 1 | — | |
| Peter Hebert | 10% owner | — | $5.0M | 1 | — | |
| Kenneth C. Frazier | Director | — | $2.0M | 1 | — | |
| Foresite Capital Management V, LLC | 10% owner | — | $1.0M | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Peter Svennilson 10% owner | Purchase | 89,200 | $11.56 | $1.0M | 89,200 | |
traded | Tim Kutzkey 10% owner | Purchase | 1,437,323 | $18.00 | $25.9M | 4,312,139 | |
traded | Peter Svennilson 10% owner | Purchase | 680,437 | $18.00 | $12.2M | Multiple accounts | |
traded | Foresite Capital Management V, LLC 10% owner | Purchase | 55,555 | $18.00 | $1.0M | 1,318,983 | |
traded | Peter Hebert 10% owner | Purchase | 277,776 | $18.00 | $5.0M | 138,888 | |
traded | Josh Wolfe Director | Purchase | 277,776 | $18.00 | $5.0M | 138,888 | |
traded | Kenneth C. Frazier Director | Purchase | 111,111 | $18.00 | $2.0M | 111,111 |
GET /stocks/filings/vX/form-4?tickers=EIKN&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"EIKN"
],
"issuer_cik": "0001861123",
"owner_cik": "0001796354",
"accession_number": "0001193125-26-385268",
"form_type": "4",
"filing_date": "2026-09-08",
"period_of_report": "2026-09-03",
"issuer_name": "Eikon Therapeutics, Inc.",
"issuer_trading_symbol": "EIKN",
"owner_name": "Column Group IV, LP",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-03",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 89200,
"transaction_price_per_share": 11.5588,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 89200,
"transaction_value": 1031044.96,
"direct_or_indirect": "I",
"nature_of_ownership": "See footnote",
"footnotes": [
{
"id": "F1",
"description": "The price reported in column 4 is a weighted average price. The securities were purchased in multiple transactions at prices ranging from $11.17 to $11.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote."
},
{
"id": "F2",
"description": "The securities are directly held by Peter Svennilson."
}
]
},
{
"tickers": [
"EIKN"
],
"issuer_cik": "0001861123",
"owner_cik": "0001931825",
"accession_number": "0001193125-26-385268",
"form_type": "4",
"filing_date": "2026-09-08",
"period_of_report": "2026-09-03",
"issuer_name": "Eikon Therapeutics, Inc.",
"issuer_trading_symbol": "EIKN",
"owner_name": "Column Group Opportunity III, LP",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-03",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 89200,
"transaction_price_per_share": 11.5588,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 89200,
"transaction_value": 1031044.96,
"direct_or_indirect": "I",
"nature_of_ownership": "See footnote",
"footnotes": [
{
"id": "F1",
"description": "The price reported in column 4 is a weighted average price. The securities were purchased in multiple transactions at prices ranging from $11.17 to $11.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote."
},
{
"id": "F2",
"description": "The securities are directly held by Peter Svennilson."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 28 records
- Other28 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
How current is EIKN’s insider data?
These are EIKN Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track EIKN insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for EIKN every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.